Mike Evers, Author at ORTHOWORLD

Episurf Continues to Gather Clinical Evidence During Early Commercialization Efforts

Episurf continued to focus on gathering clinical evidence during its early commercialization efforts in 3Q19. Sales grew 13.4% on orders from Germany.

Oct 28, 2019

Anika Therapeutics Transforms to Hybrid Commercial Model

Company Revenue The Numbers

In 3Q19, Anika completed the buildout of their U.S. hybrid commercial model while achieving double-digit revenue growth driven by MONOVISC and CINGAL.

Oct 25, 2019

Integra LifeSciences Sees Modest Orthopedic Growth from Dedicated Sales Channel

Company Revenue The Numbers

A dedicated sales channel and new products brought low single-digit orthopedic growth to Integra LifeSciences in 3Q19, driven by ankle and shoulder sales.

Oct 25, 2019

Safe Orthopaedics Grows 40% in 3Q19 on Indirect Sales Distributors

Company Revenue The Numbers

Safe Orthopaedics achieved record growth in 3Q19 on the strength of distributors and partnerships in Japan that grew indirect sales by 124%.

Oct 15, 2019

DePuy Synthes Up 1.2% in 3Q19 on Trauma Growth

Company Revenue The Numbers

DePuy Synthes made modest progress in the quarter with strong trauma sales but lost US spine and knee share to competitors.

Oct 15, 2019

Orthopedic Public Companies Grow 2.6% YoY in Quarter

Market Analysis The Numbers

The second quarter of 2019 brought incremental improvement over the first. Stryker and Medtronic saw revenue growth in the mid-single digits, Smith Nephew performed at 1.6% and DePuy Synthes and Zimmer Biomet experienced a year-over-year loss. Price pressure was a common theme in the quarter for many companies, as it offset some gains made from increased surgical volumes for the reporting period.

Sep 20, 2019